Edition:
United States

CytomX Therapeutics Inc (CTMX.OQ)

CTMX.OQ on NASDAQ Stock Exchange Global Select Market

16.96USD
4:00pm EDT
Change (% chg)

$-0.02 (-0.12%)
Prev Close
$16.98
Open
$16.90
Day's High
$17.25
Day's Low
$16.24
Volume
95,952
Avg. Vol
177,533
52-wk High
$34.98
52-wk Low
$15.16

Chart for

About

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development... (more)

Overall

Beta: --
Market Cap(Mil.): $792.65
Shares Outstanding(Mil.): 36.87
Dividend: --
Yield (%): --

Financials

  CTMX.OQ Industry Sector
P/E (TTM): -- 85.92 33.73
EPS (TTM): -1.70 -- --
ROI: -26.13 0.63 14.31
ROE: -81.04 1.68 16.04

BRIEF-CytomX Therapeutics Q1 Revenue $14.2 Mln Vs I/B/E/S View $16.4 Mln

* CYTOMX THERAPEUTICS ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS

May 09 2018

Competitors

  Price Chg
AstraZeneca plc (AZN.L) 5,860.00 +97.00
GlaxoSmithKline plc (GSK.L) 1,494.40 +8.40
Merck & Co., Inc. (MRK.N) $71.82 +0.60
Novartis AG (NOVN.S) CHF84.28 +0.20
Pfizer Inc. (PFE.N) $44.57 +0.64
Roche Holding Ltd. (ROG.S) CHF236.00 -4.55
Roche Holding Ltd. (RO.S) CHF236.20 -4.80
Sanofi SA (SASY.PA) €77.21 --
ImmunoGen, Inc. (IMGN.OQ) $7.92 -0.09
Seattle Genetics, Inc. (SGEN.OQ) $74.60 -0.15

Earnings vs. Estimates